E
72.95
-0.99 (-1.34%)
| Previous Close | 73.94 |
| Open | 73.17 |
| Volume | 3,937,506 |
| Avg. Volume (3M) | 4,500,135 |
| Market Cap | 42,828,947,456 |
| Price / Earnings (TTM) | 30.52 |
| Price / Earnings (Forward) | 27.86 |
| Price / Sales | 7.97 |
| Price / Book | 4.27 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Barclays, 30.23%) | Buy |
| 95.00 (Mizuho, 30.23%) | Buy | |
| Median | 88.00 (20.63%) | |
| Low | 79.00 (Baird, 8.29%) | Hold |
| Average | 87.58 (20.06%) | |
| Total | 8 Buy, 4 Hold | |
| Avg. Price @ Call | 79.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 07 Oct 2025 | 88.00 (20.63%) | Buy | 76.72 |
| 25 Jul 2025 | 80.00 (9.66%) | Hold | 80.00 | |
| Stifel | 22 Sep 2025 | 85.00 (16.52%) | Buy | 73.75 |
| 25 Jul 2025 | 95.00 (30.23%) | Buy | 80.00 | |
| Wells Fargo | 07 Aug 2025 | 88.00 (20.63%) | Buy | 77.93 |
| 25 Jul 2025 | 84.00 (15.15%) | Buy | 80.00 | |
| Baird | 25 Jul 2025 | 79.00 (8.29%) | Hold | 80.00 |
| Barclays | 25 Jul 2025 | 95.00 (30.23%) | Buy | 80.00 |
| Canaccord Genuity | 25 Jul 2025 | 81.00 (11.03%) | Hold | 80.00 |
| Deutsche Bank | 25 Jul 2025 | 94.00 (28.86%) | Buy | 80.00 |
| JP Morgan | 25 Jul 2025 | 85.00 (16.52%) | Hold | 80.00 |
| Mizuho | 25 Jul 2025 | 95.00 (30.23%) | Buy | 80.00 |
| Piper Sandler | 25 Jul 2025 | 90.00 (23.37%) | Buy | 80.00 |
| RBC Capital | 25 Jul 2025 | 89.00 (22.00%) | Buy | 80.00 |
| Truist Securities | 25 Jul 2025 | 82.00 (12.41%) | Hold | 80.00 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2025 | Announcement | Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care |
| 19 Aug 2025 | Announcement | Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase |
| 06 Aug 2025 | Announcement | Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve |
| 24 Jul 2025 | Announcement | Edwards Lifesciences Reports Second Quarter Results |
| 18 Jul 2025 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |